1.36BMarket Cap-8985P/E (TTM)
9.495High9.090Low635.34KVolume9.300Open9.310Pre Close5.90MTurnover0.50%Turnover RatioLossP/E (Static)148.63MShares11.31052wk High14.95P/B1.18BFloat Cap1.99552wk Low--Dividend TTM128.47MShs Float44.190Historical High--Div YieldTTM4.35%Amplitude1.995Historical Low9.286Avg Price1Lot Size
Ocular Therapeutix Stock Forum
$325 Million Private Placement Secured By Propeling Medical Company
This funding is expected to significantly propel the company's research and development endeavors, especially the clinical development of AXPAXLI™ for wet AMD treatment. Wet AMD is a chronic eye disorder that causes blurred vision or a blind spot in your visual field. It's generally caused by abnormal blood vessels that leak fluid or blood into the region of the macula. $Ocular Therapeutix(OCUL.US)$
...
News
Dow Jones· 2 mins ago
$Tellurian(TELL.US)$$Meta Materials(MMAT.US)$$Ocular Therapeutix(OCUL.US)$$Canaan(CAN.US)$$Bitfarms(BITF.US)$$SeaStar Medical(ICU.US)$
📊⚡️📊
Update
$XBI: Biotech Sector's Potential Outperformance in 2024, Especially Pre-Election Volatility in 1H
The biotech sector faced challenges in the previous year, mainly attributed to high inflation and interest rates, particularly impacting small-cap biotech firms in the difficult fundraising environment of summer 2023.
As a consequence, numerous companies experienced a significant drop in their market caps, with some even falling below the 100 million mark, a rarity...
👀
No comment yet